These findings highlight a PARylator-centered mechanism that augments PARP1-dependent DNA repair and suggesting PARylator as a potential target to sensitize ESCC to DNA‐damaging therapies. This evidence concerns the gene PARP1 and esophageal squamous cell carcinoma.